CN114835862A - A hydrogel tissue-engineered labral scaffold and its photocuring 3D printing preparation method, and photosensitive resin - Google Patents
A hydrogel tissue-engineered labral scaffold and its photocuring 3D printing preparation method, and photosensitive resin Download PDFInfo
- Publication number
- CN114835862A CN114835862A CN202210786271.9A CN202210786271A CN114835862A CN 114835862 A CN114835862 A CN 114835862A CN 202210786271 A CN202210786271 A CN 202210786271A CN 114835862 A CN114835862 A CN 114835862A
- Authority
- CN
- China
- Prior art keywords
- acrylate
- parts
- photosensitive resin
- labral
- polyol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920005989 resin Polymers 0.000 title claims abstract description 58
- 239000011347 resin Substances 0.000 title claims abstract description 58
- 239000000017 hydrogel Substances 0.000 title claims abstract description 39
- 238000010146 3D printing Methods 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 238000000016 photochemical curing Methods 0.000 title claims abstract description 18
- 239000004814 polyurethane Substances 0.000 claims abstract description 37
- 229920002635 polyurethane Polymers 0.000 claims abstract description 37
- 239000000839 emulsion Substances 0.000 claims abstract description 23
- 239000000178 monomer Substances 0.000 claims abstract description 23
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 125000000542 sulfonic acid group Chemical group 0.000 claims abstract description 9
- GBNDTYKAOXLLID-UHFFFAOYSA-N zirconium(4+) ion Chemical compound [Zr+4] GBNDTYKAOXLLID-UHFFFAOYSA-N 0.000 claims abstract description 9
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 229920005862 polyol Polymers 0.000 claims description 27
- 150000003077 polyols Chemical class 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 21
- 150000002009 diols Chemical class 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- -1 polyethylene Polymers 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 239000008367 deionised water Substances 0.000 claims description 12
- 229910021641 deionized water Inorganic materials 0.000 claims description 12
- 239000003054 catalyst Substances 0.000 claims description 9
- 125000005442 diisocyanate group Chemical group 0.000 claims description 9
- PSGCQDPCAWOCSH-UHFFFAOYSA-N (4,7,7-trimethyl-3-bicyclo[2.2.1]heptanyl) prop-2-enoate Chemical compound C1CC2(C)C(OC(=O)C=C)CC1C2(C)C PSGCQDPCAWOCSH-UHFFFAOYSA-N 0.000 claims description 8
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 239000003960 organic solvent Substances 0.000 claims description 8
- 238000006116 polymerization reaction Methods 0.000 claims description 8
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 claims description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- VFHVQBAGLAREND-UHFFFAOYSA-N diphenylphosphoryl-(2,4,6-trimethylphenyl)methanone Chemical compound CC1=CC(C)=CC(C)=C1C(=O)P(=O)(C=1C=CC=CC=1)C1=CC=CC=C1 VFHVQBAGLAREND-UHFFFAOYSA-N 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 7
- 239000005057 Hexamethylene diisocyanate Substances 0.000 claims description 6
- GUCYFKSBFREPBC-UHFFFAOYSA-N [phenyl-(2,4,6-trimethylbenzoyl)phosphoryl]-(2,4,6-trimethylphenyl)methanone Chemical compound CC1=CC(C)=CC(C)=C1C(=O)P(=O)(C=1C=CC=CC=1)C(=O)C1=C(C)C=C(C)C=C1C GUCYFKSBFREPBC-UHFFFAOYSA-N 0.000 claims description 6
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- QNILTEGFHQSKFF-UHFFFAOYSA-N n-propan-2-ylprop-2-enamide Chemical compound CC(C)NC(=O)C=C QNILTEGFHQSKFF-UHFFFAOYSA-N 0.000 claims description 6
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 5
- 229920001451 polypropylene glycol Polymers 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 claims description 4
- PTBDIHRZYDMNKB-UHFFFAOYSA-N 2,2-Bis(hydroxymethyl)propionic acid Chemical compound OCC(C)(CO)C(O)=O PTBDIHRZYDMNKB-UHFFFAOYSA-N 0.000 claims description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 4
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 4
- 239000004698 Polyethylene Substances 0.000 claims description 4
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 4
- NIMLQBUJDJZYEJ-UHFFFAOYSA-N isophorone diisocyanate Chemical compound CC1(C)CC(N=C=O)CC(C)(CN=C=O)C1 NIMLQBUJDJZYEJ-UHFFFAOYSA-N 0.000 claims description 4
- 229920005906 polyester polyol Polymers 0.000 claims description 4
- 229920000570 polyether Polymers 0.000 claims description 4
- 229920000573 polyethylene Polymers 0.000 claims description 4
- 229920000098 polyolefin Polymers 0.000 claims description 4
- 229920005749 polyurethane resin Polymers 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- BWYYYTVSBPRQCN-UHFFFAOYSA-M sodium;ethenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C=C BWYYYTVSBPRQCN-UHFFFAOYSA-M 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 3
- 239000012948 isocyanate Substances 0.000 claims description 3
- 150000002513 isocyanates Chemical group 0.000 claims description 3
- 229920001610 polycaprolactone Polymers 0.000 claims description 3
- 239000004632 polycaprolactone Substances 0.000 claims description 3
- 229920000909 polytetrahydrofuran Polymers 0.000 claims description 3
- VSFOXJWBPGONDR-UHFFFAOYSA-M potassium;3-prop-2-enoyloxypropane-1-sulfonate Chemical compound [K+].[O-]S(=O)(=O)CCCOC(=O)C=C VSFOXJWBPGONDR-UHFFFAOYSA-M 0.000 claims description 3
- MYWOJODOMFBVCB-UHFFFAOYSA-N 1,2,6-trimethylphenanthrene Chemical compound CC1=CC=C2C3=CC(C)=CC=C3C=CC2=C1C MYWOJODOMFBVCB-UHFFFAOYSA-N 0.000 claims description 2
- DZSVIVLGBJKQAP-UHFFFAOYSA-N 1-(2-methyl-5-propan-2-ylcyclohex-2-en-1-yl)propan-1-one Chemical compound CCC(=O)C1CC(C(C)C)CC=C1C DZSVIVLGBJKQAP-UHFFFAOYSA-N 0.000 claims description 2
- ZDQNWDNMNKSMHI-UHFFFAOYSA-N 1-[2-(2-prop-2-enoyloxypropoxy)propoxy]propan-2-yl prop-2-enoate Chemical compound C=CC(=O)OC(C)COC(C)COCC(C)OC(=O)C=C ZDQNWDNMNKSMHI-UHFFFAOYSA-N 0.000 claims description 2
- YIKSHDNOAYSSPX-UHFFFAOYSA-N 1-propan-2-ylthioxanthen-9-one Chemical compound S1C2=CC=CC=C2C(=O)C2=C1C=CC=C2C(C)C YIKSHDNOAYSSPX-UHFFFAOYSA-N 0.000 claims description 2
- LCHAFMWSFCONOO-UHFFFAOYSA-N 2,4-dimethylthioxanthen-9-one Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(C)=C3SC2=C1 LCHAFMWSFCONOO-UHFFFAOYSA-N 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims description 2
- RZVINYQDSSQUKO-UHFFFAOYSA-N 2-phenoxyethyl prop-2-enoate Chemical compound C=CC(=O)OCCOC1=CC=CC=C1 RZVINYQDSSQUKO-UHFFFAOYSA-N 0.000 claims description 2
- 239000005058 Isophorone diisocyanate Substances 0.000 claims description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 2
- 239000005062 Polybutadiene Substances 0.000 claims description 2
- DAKWPKUUDNSNPN-UHFFFAOYSA-N Trimethylolpropane triacrylate Chemical compound C=CC(=O)OCC(CC)(COC(=O)C=C)COC(=O)C=C DAKWPKUUDNSNPN-UHFFFAOYSA-N 0.000 claims description 2
- 238000012644 addition polymerization Methods 0.000 claims description 2
- RWCCWEUUXYIKHB-UHFFFAOYSA-N benzophenone Chemical compound C=1C=CC=CC=1C(=O)C1=CC=CC=C1 RWCCWEUUXYIKHB-UHFFFAOYSA-N 0.000 claims description 2
- 239000012965 benzophenone Substances 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims description 2
- KCWDJXPPZHMEIK-UHFFFAOYSA-N isocyanic acid;toluene Chemical class N=C=O.N=C=O.CC1=CC=CC=C1 KCWDJXPPZHMEIK-UHFFFAOYSA-N 0.000 claims description 2
- CRVGTESFCCXCTH-UHFFFAOYSA-N methyl diethanolamine Chemical compound OCCN(C)CCO CRVGTESFCCXCTH-UHFFFAOYSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- NWVVVBRKAWDGAB-UHFFFAOYSA-N p-methoxyphenol Chemical compound COC1=CC=C(O)C=C1 NWVVVBRKAWDGAB-UHFFFAOYSA-N 0.000 claims description 2
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 2
- 229920002857 polybutadiene Polymers 0.000 claims description 2
- 239000004626 polylactic acid Substances 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- XFTALRAZSCGSKN-UHFFFAOYSA-M sodium;4-ethenylbenzenesulfonate Chemical compound [Na+].[O-]S(=O)(=O)C1=CC=C(C=C)C=C1 XFTALRAZSCGSKN-UHFFFAOYSA-M 0.000 claims description 2
- 150000003512 tertiary amines Chemical group 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims 11
- 230000001804 emulsifying effect Effects 0.000 claims 2
- GNSFRPWPOGYVLO-UHFFFAOYSA-N 3-hydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCCO GNSFRPWPOGYVLO-UHFFFAOYSA-N 0.000 claims 1
- QZPSOSOOLFHYRR-UHFFFAOYSA-N 3-hydroxypropyl prop-2-enoate Chemical compound OCCCOC(=O)C=C QZPSOSOOLFHYRR-UHFFFAOYSA-N 0.000 claims 1
- FIHBHSQYSYVZQE-UHFFFAOYSA-N 6-prop-2-enoyloxyhexyl prop-2-enoate Chemical compound C=CC(=O)OCCCCCCOC(=O)C=C FIHBHSQYSYVZQE-UHFFFAOYSA-N 0.000 claims 1
- BBAGPRAUWBSYDH-UHFFFAOYSA-N C(C)OP(OC(C1=C(C=C(C=C1C)C)C)=O)=O Chemical compound C(C)OP(OC(C1=C(C=C(C=C1C)C)C)=O)=O BBAGPRAUWBSYDH-UHFFFAOYSA-N 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- FSDNTQSJGHSJBG-UHFFFAOYSA-N piperidine-4-carbonitrile Chemical compound N#CC1CCNCC1 FSDNTQSJGHSJBG-UHFFFAOYSA-N 0.000 claims 1
- 150000005846 sugar alcohols Polymers 0.000 claims 1
- 238000007639 printing Methods 0.000 abstract description 26
- 210000001519 tissue Anatomy 0.000 abstract description 16
- 230000002579 anti-swelling effect Effects 0.000 abstract description 14
- 238000001727 in vivo Methods 0.000 abstract description 6
- 230000008439 repair process Effects 0.000 abstract description 6
- 210000001188 articular cartilage Anatomy 0.000 abstract description 4
- 238000012805 post-processing Methods 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract description 2
- 230000003848 cartilage regeneration Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 28
- 238000001723 curing Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 210000004394 hip joint Anatomy 0.000 description 6
- 208000014674 injury Diseases 0.000 description 6
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 6
- 230000007547 defect Effects 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 229920000536 2-Acrylamido-2-methylpropane sulfonic acid Polymers 0.000 description 4
- XHZPRMZZQOIPDS-UHFFFAOYSA-N 2-Methyl-2-[(1-oxo-2-propenyl)amino]-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(C)(C)NC(=O)C=C XHZPRMZZQOIPDS-UHFFFAOYSA-N 0.000 description 4
- FKXJWELJXMKBDI-UHFFFAOYSA-K [butyl-di(dodecanoyloxy)stannyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)O[Sn](CCCC)(OC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCC FKXJWELJXMKBDI-UHFFFAOYSA-K 0.000 description 4
- 238000004821 distillation Methods 0.000 description 4
- 238000002296 dynamic light scattering Methods 0.000 description 4
- UHESRSKEBRADOO-UHFFFAOYSA-N ethyl carbamate;prop-2-enoic acid Chemical compound OC(=O)C=C.CCOC(N)=O UHESRSKEBRADOO-UHFFFAOYSA-N 0.000 description 4
- 238000009775 high-speed stirring Methods 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000010907 mechanical stirring Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 210000002435 tendon Anatomy 0.000 description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 210000000588 acetabulum Anatomy 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000001179 synovial fluid Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000001258 synovial membrane Anatomy 0.000 description 2
- KSBAEPSJVUENNK-UHFFFAOYSA-L tin(ii) 2-ethylhexanoate Chemical compound [Sn+2].CCCCC(CC)C([O-])=O.CCCCC(CC)C([O-])=O KSBAEPSJVUENNK-UHFFFAOYSA-L 0.000 description 2
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 2
- 229910052726 zirconium Inorganic materials 0.000 description 2
- GTEXIOINCJRBIO-UHFFFAOYSA-N 2-[2-(dimethylamino)ethoxy]-n,n-dimethylethanamine Chemical compound CN(C)CCOCCN(C)C GTEXIOINCJRBIO-UHFFFAOYSA-N 0.000 description 1
- VFZKVQVQOMDJEG-UHFFFAOYSA-N 2-prop-2-enoyloxypropyl prop-2-enoate Chemical compound C=CC(=O)OC(C)COC(=O)C=C VFZKVQVQOMDJEG-UHFFFAOYSA-N 0.000 description 1
- NYUTUWAFOUJLKI-UHFFFAOYSA-N 3-prop-2-enoyloxypropane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCOC(=O)C=C NYUTUWAFOUJLKI-UHFFFAOYSA-N 0.000 description 1
- 239000004925 Acrylic resin Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 208000023803 Hip injury Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010060820 Joint injury Diseases 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 208000012285 hip pain Diseases 0.000 description 1
- 230000002706 hydrostatic effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 229920000921 polyethylene adipate Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- LYBIZMNPXTXVMV-UHFFFAOYSA-N propan-2-yl prop-2-enoate Chemical compound CC(C)OC(=O)C=C LYBIZMNPXTXVMV-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F283/00—Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass C08G
- C08F283/006—Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass C08G on to polymers provided for in C08G18/00
- C08F283/008—Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass C08G on to polymers provided for in C08G18/00 on to unsaturated polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/52—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B33—ADDITIVE MANUFACTURING TECHNOLOGY
- B33Y—ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3-D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3-D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING
- B33Y70/00—Materials specially adapted for additive manufacturing
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2/00—Processes of polymerisation
- C08F2/46—Polymerisation initiated by wave energy or particle radiation
- C08F2/48—Polymerisation initiated by wave energy or particle radiation by ultraviolet or visible light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/06—Materials or treatment for tissue regeneration for cartilage reconstruction, e.g. meniscus
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Dispersion Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- Manufacturing & Machinery (AREA)
- Engineering & Computer Science (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
- Macromonomer-Based Addition Polymer (AREA)
Abstract
本发明公开了一种高强度抗溶胀水凝胶型组织工程盂唇支架及其光固化3D打印制备方法、光敏树脂。打印支架所用光敏树脂的原料组分按质量份数计,含量如下:聚氨酯甲基丙烯酸酯乳液:10~50份,水溶性光固化单体10~30份,油溶性光固化单体10~30份,含磺酸基团光固化单体10~30份,光引发剂0.1~5份。打印完成的水凝胶支架浸入锆离子溶液中后处理,得到高强度抗溶胀水凝胶支架。本发明的水凝胶型盂唇支架为多孔结构,具有优异力学性能,其力学性能与天然盂唇相近,具有良好生物相容性和体内稳定性,而且光固化3D打印可以精确控制其三维结构。动物体内实验结果表明该水凝胶型盂唇支架具有良好保护关节软骨及促进软骨再生修复的作用。
The invention discloses a high-strength anti-swelling hydrogel tissue engineering labral support, a preparation method for photocuring 3D printing, and a photosensitive resin. The raw material components of the photosensitive resin used for printing the bracket are calculated in parts by mass, and the contents are as follows: polyurethane methacrylate emulsion: 10-50 parts, water-soluble photo-curable monomer 10-30 parts, oil-soluble photo-curable monomer 10-30 parts parts, 10-30 parts of sulfonic acid group-containing photocurable monomer, and 0.1-5 parts of photoinitiator. The printed hydrogel scaffold was immersed in a zirconium ion solution for post-processing to obtain a high-strength anti-swelling hydrogel scaffold. The hydrogel labral support of the present invention has a porous structure and has excellent mechanical properties. . The results of animal in vivo experiments show that the hydrogel labral scaffold has the functions of protecting articular cartilage and promoting cartilage regeneration and repair.
Description
技术领域technical field
本发明属于组织工程技术领域,具体涉及一种高强度抗溶胀水凝胶型组织工程盂唇支架及其光固化3D打印制备方法、光敏树脂。The invention belongs to the technical field of tissue engineering, and in particular relates to a high-strength anti-swelling hydrogel tissue engineering labral support, a preparation method for photocuring 3D printing, and a photosensitive resin.
背景技术Background technique
髋臼盂唇是附着于髋臼边缘的纤维软骨结构,在髋臼切迹处与髋臼横韧带相连,与之形成完整的环状结构。髋臼盂唇撕裂是最常见的髋关节损伤,在90%的髋关节镜手术中均可发现不同程度的髋臼盂唇损伤[Arthroscopy, 2005, 21, 1496-1504],是髋关节疼痛的常见原因之一。髋臼盂唇具有稳定髋关节与调节滑液平衡的功能[Am J Sport Med,2013, 41, 1750-1756]。由于髋臼盂唇组织结构特殊,无神经及淋巴系统,且仅周边1/3有血液供应,因此盂唇自身缺乏有效的修复能力,损伤后难以恢复。髋臼盂唇的损伤可导致髋关节不稳及关节内滑液分布不均,使得关节腔内滑液的流体静水压减小、髋关节内应力增大,从而加速髋关节老化、退变,最终形成骨性关节炎。其不仅会造成患者长期的髋关节疼痛,还会导致患者在日常生活中出现机械性交锁等症状,同时可伴有一定程度的关节活动度受限。对于运动员群体,髋臼盂唇的损伤会影响其训练及比赛,使其运动水平显著下降,甚至最终导致运动生涯的终结[Am J Sport Med, 2013, 41, 444-460];对于非运动员群体,其损伤会引起关节的活动功能障碍,影响日常生活及工作,远期可导致严重的骨性关节炎甚至关节病残。由此可见,对于髋臼盂唇损伤的进一步研究具有十分重要的临床意义。The acetabular labrum is a fibrocartilaginous structure attached to the acetabular rim and is connected to the transverse acetabular ligament at the acetabular notch to form a complete annular structure. Acetabular labral tear is the most common hip injury, and can be found in 90% of hip arthroscopy procedures [Arthroscopy, 2005, 21, 1496-1504]. one of the common reasons. The acetabular labrum has the function of stabilizing the hip joint and regulating synovial fluid balance [Am J Sport Med, 2013, 41, 1750-1756]. Due to the special tissue structure of the acetabular labrum, there is no nerve and lymphatic system, and only the peripheral 1/3 has blood supply, so the labrum itself lacks effective repair ability, and it is difficult to recover after injury. The injury of the acetabular labrum can lead to instability of the hip joint and uneven distribution of synovial fluid in the joint, which reduces the hydrostatic pressure of synovial fluid in the joint cavity and increases the internal stress of the hip joint, thereby accelerating the aging and degeneration of the hip joint. , eventually forming osteoarthritis. It will not only cause long-term hip pain in patients, but also lead to symptoms such as mechanical locking in daily life, and may be accompanied by a certain degree of limitation of joint mobility. For athletes, acetabular labrum injuries can affect their training and competition, significantly reduce their performance levels, and eventually lead to the end of their sports careers [Am J Sport Med, 2013, 41, 444-460]; for non-athletic groups , its damage will cause joint dysfunction, affecting daily life and work, and can lead to severe osteoarthritis and even joint disability in the long run. It can be seen that further research on acetabular labrum injury has very important clinical significance.
目前针对髋臼盂唇损伤的治疗方法主要包括盂唇切除、盂唇缝合以及盂唇重建。在盂唇切除术后早期,患者的疼痛能够得到明显缓解,但是盂唇的部分缺失会影响盂唇的完整性,从而显著影响其生理功能。研究表明,即使小部分的盂唇切除,也会导致其生理功能的大幅度丧失,调节关节内液体压力传导的能力下降超过50%。盂唇缝合术同样具有一定的限制性。由于髋臼盂唇仅周边1/3血供丰富,手术需经其基底部缝合后才有盂唇愈合的可能。髋臼盂唇较差的自身修复能力限制了盂唇缝合修补术的临床应用。盂唇重建作为目前治疗髋臼盂唇损伤的新兴手术方式,对缺损部位的软骨能够起到很好的保护作用。目前临床常用的是自体肌腱移植技术,即将自体肌腱修整为圆柱状,通过带线锚钉固定在盂唇缺失的部位,以替代盂唇组织。临床研究证实,利用自体肌腱重建盂唇后,患者的功能评分得到部分改善。然而,盂唇重建手术仍存在自体肌腱取腱部位疼痛,以及取材有限等不足。组织工程技术为当前盂唇重建手术的进一步开展提供了很好的选择,从而解决现有术式的不足之处。将生物相容性好的生物支架材料制作为移植物,并将其植入组织缺损部位以修复组织甚至器官的缺损,从而替代缺损组织发挥其生物学功能。理想的生物支架材料应该具有以下特征:1、有一定的初始强度及良好的力学性能,并且与天然盂唇组织的力学强度接近,最大拉伸强度应在4-12 MPa范围内,拉伸弹性模量在26-30 MPa范围内;2、具有较好的组织相容性,较少有排斥反应;3、多孔结构,修复细胞能够进入修复材料的空隙,以便干细胞粘附、增殖及分化。然而,目前的相关研究尚未发现理想的组织工程材料用于盂唇组织修复。The current treatment methods for acetabular labral injury mainly include labral resection, labral suture, and labral reconstruction. In the early postoperative period after labrumectomy, the patient's pain can be significantly relieved, but the partial absence of the labrum can affect the integrity of the labrum, thereby significantly affecting its physiological function. Studies have shown that even a small portion of the labrum is removed, resulting in a substantial loss of its physiological function and a more than 50% reduction in the ability to regulate fluid pressure conduction within the joint. Labral suture also has certain limitations. Since only the peripheral 1/3 of the acetabular labrum is rich in blood supply, the labrum can be healed only after the basal suture is sutured. The poor self-repair ability of the acetabular labrum limits the clinical application of labral suture repair. Labrum reconstruction, as an emerging surgical method for the treatment of acetabular labral injury, can protect the cartilage at the defect site very well. At present, autologous tendon transplantation is commonly used in clinical practice, that is, the autologous tendon is trimmed into a cylindrical shape and fixed in the missing part of the labrum with thread anchors to replace the labrum tissue. Clinical studies confirmed that the functional score of patients was partially improved after labrum reconstruction with autologous tendon. However, labral reconstruction surgery still suffers from pain at the site of autologous tendon extraction and limited access. Tissue engineering technology provides a good choice for the further development of the current labral reconstruction surgery, so as to solve the shortcomings of the existing surgical methods. The biocompatible bioscaffold material is made as a graft, and it is implanted into the tissue defect site to repair the defect of the tissue or even the organ, so as to replace the defective tissue to exert its biological function. The ideal bioscaffold material should have the following characteristics: 1. It has a certain initial strength and good mechanical properties, and is close to the mechanical strength of the natural labral tissue, the maximum tensile strength should be in the range of 4-12 MPa, and the tensile elasticity The modulus is in the range of 26-30 MPa; 2. It has good histocompatibility and less rejection; 3. Porous structure, repair cells can enter the gaps of repair materials, so that stem cells can adhere, proliferate and differentiate. However, current related studies have not found an ideal tissue engineering material for labral tissue repair.
发明内容SUMMARY OF THE INVENTION
本发明的目的在于提供一种高强度抗溶胀水凝胶型组织工程盂唇支架及其光固化3D打印制备方法。The purpose of the present invention is to provide a high-strength anti-swelling hydrogel tissue-engineered labral support and a preparation method thereof by photocuring 3D printing.
本发明制备的组织工程盂唇具有良好的生物相容性,体内实验证明其具有良好的体内稳定性,而且制备的盂唇支架具有与天然盂唇相近的力学性能。此外,本发明采用打印精度最高的光固化3D打印,制备的盂唇支架表面光滑,可以定制特定三维结构和多孔结构的盂唇支架。The tissue engineered labrum prepared by the invention has good biocompatibility, and the in vivo experiment proves that it has good in vivo stability, and the prepared labrum support has mechanical properties similar to the natural labrum. In addition, the present invention adopts photocuring 3D printing with the highest printing accuracy, and the prepared labral support has a smooth surface, and can customize a labral support with a specific three-dimensional structure and a porous structure.
本发明所提供的高强度抗溶胀水凝胶型组织工程盂唇支架的光固化3D打印制备方法,包括下述步骤:The light-curing 3D printing preparation method of the high-strength anti-swelling hydrogel tissue engineering labral stent provided by the present invention comprises the following steps:
1)制备光敏树脂,所述光敏树脂的原料组分按质量份数计含量如下:1) Prepare a photosensitive resin, the raw material components of the photosensitive resin are as follows in parts by mass:
水性聚氨酯(甲基)丙烯酸酯乳液 10~50份Waterborne polyurethane (meth)acrylate emulsion 10 to 50 parts
水溶性光固化单体 10~30份10~30 parts of water-soluble photocurable monomer
油溶性光固化单体 10~30份Oil-soluble photocurable monomer 10~30 parts
含磺酸基团光固化单体 10~30份10~30 parts of photocurable monomer containing sulfonic acid group
光引发剂 0.1~5份;Photoinitiator 0.1 to 5 parts;
2)将步骤1)所述光敏树脂进行光固化3D打印,得到盂唇模型坯体;2) Perform photocuring 3D printing on the photosensitive resin in step 1) to obtain a labrum model blank;
3)将所述盂唇模型坯体浸入锆离子溶液中后处理,最终得到高强度抗溶胀水凝胶型组织工程盂唇支架。3) The labrum model green body is immersed in a zirconium ion solution for post-processing, and finally a high-strength anti-swelling hydrogel tissue-engineered labral scaffold is obtained.
上述方法步骤1)中,所述聚氨酯(甲基)丙烯酸酯乳液,其先由二异氰酸酯与羟基封端的多元醇及带亲水基团的二元醇反应或由二异氰酸酯与羟基封端的多元醇及含亲水链段的多元醇反应,得到异氰酸酯基封端的预聚物;然后与含羟基的(甲基)丙烯酸酯反应制备得到聚氨酯(甲基)丙烯酸酯树脂,再经过乳化制备得到水性聚氨酯(甲基)丙烯酸酯乳液。In step 1) of the above method, the polyurethane (meth)acrylate emulsion is firstly reacted with diisocyanate and hydroxyl-terminated polyol and diol with hydrophilic group or by diisocyanate and hydroxyl-terminated polyol. It reacts with a polyol containing a hydrophilic segment to obtain an isocyanate group-terminated prepolymer; then reacts with a hydroxyl-containing (meth)acrylate to prepare a polyurethane (meth)acrylate resin, which is then emulsified to prepare a water-based polyurethane (Meth)acrylate emulsion.
其中,所述二异氰酸酯选自氢化苯基甲烷二异氰酸酯、异佛尔酮二异氰酸酯、六亚甲基二异氰酸酯中的至少一种。Wherein, the diisocyanate is selected from at least one of hydrogenated phenylmethane diisocyanate, isophorone diisocyanate and hexamethylene diisocyanate.
所述羟基封端的多元醇选自聚醚多元醇、聚酯多元醇、聚烯烃多元醇中的至少一种。The hydroxyl-terminated polyol is selected from at least one of polyether polyol, polyester polyol, and polyolefin polyol.
根据本发明的实施方案,所述聚醚多元醇选自聚乙二醇、聚丙二醇、聚四氢呋喃二醇中的至少一种。According to an embodiment of the present invention, the polyether polyol is selected from at least one of polyethylene glycol, polypropylene glycol, and polytetrahydrofuran glycol.
根据本发明的实施方案,所述聚酯多元醇选自聚己内酯二醇,聚乳酸二醇、聚己二酸乙二醇酯二醇、聚己二酸丁二醇酯二醇中的至少一种。According to an embodiment of the present invention, the polyester polyol is selected from the group consisting of polycaprolactone diol, polylactic acid diol, polyethylene adipate diol, and polybutylene adipate diol. at least one.
根据本发明的实施方案,所述聚烯烃多元醇选自聚丁二烯二醇。According to an embodiment of the present invention, the polyolefin polyol is selected from polybutadiene diols.
根据本发明的实施方案,所述羟基封端的多元醇数均分子量为1000~10000 g/mol。According to an embodiment of the present invention, the hydroxyl-terminated polyol has a number average molecular weight of 1000-10000 g/mol.
所述的带亲水性基团的二元醇选自2,2 -二羟甲基丙酸、N-甲基二乙醇胺中的一种。The diol with a hydrophilic group is selected from one of 2,2-dimethylolpropionic acid and N-methyldiethanolamine.
所述的含亲水链段的多元醇选自聚乙二醇、聚乙二醇-聚丙二醇嵌段共聚物中的一种。The hydrophilic segment-containing polyol is selected from the group consisting of polyethylene glycol and polyethylene glycol-polypropylene glycol block copolymer.
所述的含羟基的(甲基)丙烯酸酯选自(甲基)丙烯酸羟乙酯、(甲基)丙烯酸羟丙酯中的至少一种。The hydroxyl-containing (meth)acrylate is selected from at least one of hydroxyethyl (meth)acrylate and hydroxypropyl (meth)acrylate.
所述水性聚氨酯(甲基)丙烯酸酯乳液具体可按照包括如下步骤的方法制备得到:The water-based polyurethane (meth)acrylate emulsion can be specifically prepared according to a method comprising the following steps:
S1:在催化剂存在下,使二异氰酸酯与羟基封端的多元醇、带亲水性基团的二元醇或含亲水链段的多元醇和有机溶剂混合,发生逐步加成聚合反应得到异氰酸酯基封端的聚氨酯类树脂;S1: In the presence of a catalyst, diisocyanate is mixed with a hydroxyl-terminated polyol, a diol with a hydrophilic group or a polyol containing a hydrophilic segment and an organic solvent, and a stepwise addition polymerization reaction occurs to obtain an isocyanate-terminated polyol. Terminated polyurethane resin;
S2:将上述制备的异氰酸酯基封端的聚氨酯类树脂与含羟基的(甲基)丙烯酸酯反应,期间加入阻聚剂,得到水性聚氨酯(甲基)丙烯酸酯;S2: react the above-prepared isocyanate group-terminated polyurethane resin with a hydroxyl-containing (meth)acrylate, and add a polymerization inhibitor during the reaction to obtain water-based polyurethane (meth)acrylate;
S3:将上述制备的水性聚氨酯(甲基)丙烯酸酯乳化,得到固含量为10~30%(具体如25%)的水性聚氨酯(甲基)丙烯酸酯乳液,乳液粒径为20~200 nm(优选为20~60 nm)。S3: Emulsify the water-based polyurethane (meth)acrylate prepared above to obtain a water-based polyurethane (meth)acrylate emulsion with a solid content of 10-30% (specifically, 25%), and the emulsion particle size is 20-200 nm ( preferably 20 to 60 nm).
根据本发明的实施方案,所述的催化剂为叔胺类(如三乙烯二胺、双(二甲胺基乙基)醚)或有机金属类催化剂(如辛酸亚锡、月桂酸正丁基锡、羧酸铋);According to an embodiment of the present invention, the catalyst is a tertiary amine (such as triethylenediamine, bis(dimethylaminoethyl) ether) or an organometallic catalyst (such as stannous octoate, n-butyltin laurate, carboxylate) bismuth acid);
根据本发明的实施方案,所述有机溶剂选自丙酮、四氢呋喃中的至少一种;According to an embodiment of the present invention, the organic solvent is selected from at least one of acetone and tetrahydrofuran;
根据本发明的实施方案,所述阻聚剂选自对苯二酚、对甲氧基苯酚中的至少一种;According to an embodiment of the present invention, the polymerization inhibitor is selected from at least one of hydroquinone and p-methoxyphenol;
根据本发明的实施方案,所述步骤S1中,所述催化剂的用量为200 ~600 ppm;所述聚合反应的反应温度为50~100℃,反应时间1~12 h;According to an embodiment of the present invention, in the step S1, the amount of the catalyst used is 200-600 ppm; the reaction temperature of the polymerization reaction is 50-100°C, and the reaction time is 1-12 h;
根据本发明的实施方案,所述步骤S2中,所述阻聚剂的用量为50 ~1000 ppm;所述反应的反应温度为50~100℃,反应时间1~12 h;According to an embodiment of the present invention, in the step S2, the amount of the polymerization inhibitor used is 50-1000 ppm; the reaction temperature of the reaction is 50-100°C, and the reaction time is 1-12 h;
所述二异氰酸酯、羟基封端的多元醇、带水性基团的二元醇或含亲水链段的多元醇、含羟基的(甲基)丙烯酸酯的摩尔比为1:(0.3-0.5):(0.3-0.5):(0.4-0.8)。The molar ratio of the diisocyanate, the hydroxyl-terminated polyol, the diol with a water-based group or the polyol containing a hydrophilic segment, and the hydroxyl-containing (meth)acrylate is 1: (0.3-0.5): (0.3-0.5): (0.4-0.8).
本发明中,所述的水溶性光固化单体选自丙烯酰胺,N-异丙基丙烯酰胺、丙烯酸、甲基丙烯酸、N-乙烯基吡咯烷酮的至少一种;In the present invention, the water-soluble photocurable monomer is selected from at least one of acrylamide, N-isopropylacrylamide, acrylic acid, methacrylic acid, and N-vinylpyrrolidone;
本发明中,所述的油溶性光固化单体选自丙烯酸羟乙酯、丙烯酸异冰片酯、2-苯氧基乙基丙烯酸酯、丙烯腈、丙烯酸丁酯、甲基丙烯酸甲酯、1,6-己二醇双丙烯酸酯、二缩丙二醇双丙烯酸酯、三丙二醇二丙烯酸酯、三羟甲基丙烷三丙烯酸酯、季戊四醇四丙烯酸酯的至少一种;In the present invention, the oil-soluble photocurable monomer is selected from hydroxyethyl acrylate, isobornyl acrylate, 2-phenoxyethyl acrylate, acrylonitrile, butyl acrylate, methyl methacrylate, 1, At least one of 6-hexanediol diacrylate, propylene glycol diacrylate, tripropylene glycol diacrylate, trimethylolpropane triacrylate, and pentaerythritol tetraacrylate;
所述的含磺酸基团的光固化单体选自2-丙烯酰胺-2-甲基丙磺酸、对苯乙烯磺酸钠、乙烯基磺酸钠、3-磺丙基丙烯酸酯钾盐、卡拉胶的至少一种;The photocurable monomer containing sulfonic acid group is selected from 2-acrylamide-2-methylpropanesulfonic acid, sodium p-styrene sulfonate, sodium vinyl sulfonate, potassium 3-sulfopropyl acrylate , at least one of carrageenan;
所述的光引发剂选自(2 ,4 ,6-三甲基苯甲酰基)二苯基氧化膦、苯基双(2 ,4 ,6-三甲基苯甲酰基)氧化膦、(2 ,4 ,6-三甲基苯甲酰基)膦酸乙酯、二苯甲酮、异丙基硫杂蒽酮、2,4-二甲基硫杂蒽酮的至少一种。The photoinitiator is selected from (2,4,6-trimethylbenzoyl)diphenylphosphine oxide, phenylbis(2,4,6-trimethylbenzoyl)phosphine oxide, (2 , at least one of ethyl ,4,6-trimethylbenzoyl)phosphonate, benzophenone, isopropylthioxanthone, and 2,4-dimethylthioxanthone.
上述方法步骤1)中,优选的所述光敏树脂的原料组分按质量份数计含量如下:In the above method step 1), the preferred raw material components of the photosensitive resin are as follows in parts by mass:
水性聚氨酯(甲基)丙烯酸酯乳液 30~50份Waterborne polyurethane (meth)acrylate emulsion 30 to 50 parts
水溶性光固化单体 20~30份20~30 parts of water-soluble photocurable monomer
油溶性光固化单体 10~25份Oil-soluble photocurable monomer 10~25 parts
含磺酸基团光固化单体 10~25份10~25 parts of photocurable monomer containing sulfonic acid group
光引发剂 1~2份1 to 2 parts of photoinitiator
根据本发明的一个实施方案,所述光敏树脂的原料中各组分的质量份数为:水性聚氨酯(甲基)丙烯酸酯乳液-1 40份、丙烯酰胺 20份、丙烯酸异冰片酯19份、2-丙烯酰胺-2-甲基丙磺酸 20份、苯基双(2,4,6-三甲基苯甲酰基)氧化膦 1份。According to an embodiment of the present invention, the parts by mass of each component in the raw material of the photosensitive resin are: water-based polyurethane (meth)acrylate emulsion-1 40 parts, acrylamide 20 parts, isobornyl acrylate 19 parts, 20 parts of 2-acrylamido-2-methylpropanesulfonic acid and 1 part of phenylbis(2,4,6-trimethylbenzoyl)phosphine oxide.
根据本发明的一个实施方案,所述光敏树脂的原料中各组分的质量份数为:水性聚氨酯(甲基)丙烯酸酯乳液-1 45份、丙烯酰胺 20份、丙烯酸异冰片酯 22份、2-丙烯酰胺-2-甲基丙磺酸 11份、(2,4,6-三甲基苯甲酰基)二苯基氧化膦 2份。According to an embodiment of the present invention, the parts by mass of each component in the raw material of the photosensitive resin are: waterborne polyurethane (meth)acrylate emulsion-145 parts, acrylamide 20 parts, isobornyl acrylate 22 parts, 11 parts of 2-acrylamido-2-methylpropanesulfonic acid, and 2 parts of (2,4,6-trimethylbenzoyl)diphenylphosphine oxide.
根据本发明的一个实施方案,所述光敏树脂的原料中各组分的质量份数为:水性聚氨酯(甲基)丙烯酸酯乳液-2 45份、N-异丙基丙烯酰胺 20份、丙烯酸异冰片酯10份、3-磺丙基丙烯酸酯钾盐 24份、苯基双(2,4,6-三甲基苯甲酰基)氧化膦 1份。According to an embodiment of the present invention, the parts by mass of each component in the raw material of the photosensitive resin are: water-based polyurethane (meth)acrylate emulsion-2 45 parts, N-isopropylacrylamide 20 parts, acrylic isopropyl acrylate 10 parts of bornanyl ester, 24 parts of potassium salt of 3-sulfopropyl acrylate, 1 part of phenylbis(2,4,6-trimethylbenzoyl)phosphine oxide.
根据本发明的一个实施方案,所述光敏树脂的原料中各组分的质量份数为:水性聚氨酯(甲基)丙烯酸酯乳液-2 34份、N-异丙基丙烯酰胺 30份、丙烯腈 10份、乙烯基磺酸钠25份、(2,4,6-三甲基苯甲酰基)二苯基氧化膦 1份。According to an embodiment of the present invention, the parts by mass of each component in the raw material of the photosensitive resin are: water-based polyurethane (meth)acrylate emulsion-2 34 parts, N-isopropylacrylamide 30 parts, acrylonitrile 10 parts, 25 parts of sodium vinylsulfonate, 1 part of (2,4,6-trimethylbenzoyl) diphenylphosphine oxide.
本发明还提供上述光敏树脂的制备方法。The present invention also provides a preparation method of the above-mentioned photosensitive resin.
本发明所提供的上述光敏树脂的制备方法,包括下述步骤:按照比例称取水性聚氨酯(甲基)丙烯酸酯乳液、水性光固化单体、油溶性光固化单体、光引发剂和光吸收剂,倒入搅拌器中,在避光的条件下通过超声细胞粉碎机混匀制备。The preparation method of the above-mentioned photosensitive resin provided by the present invention includes the following steps: weighing water-based polyurethane (meth)acrylate emulsion, water-based photocurable monomer, oil-soluble photocurable monomer, photoinitiator and light absorber in proportion , poured into a blender, and prepared by mixing with an ultrasonic cell disintegrator in the dark.
上述方法步骤3)中,所述后处理过程为:将打印制备的盂唇支架坯体放入锆离子溶液中浸泡三天,再放入去离子水中浸泡三天。所述锆离子溶液中锆离子的浓度为0.01~0.3 mol/L。In step 3) of the above method, the post-processing process is as follows: the labral support blank prepared by printing is soaked in a zirconium ion solution for three days, and then placed in deionized water for three days. The concentration of zirconium ions in the zirconium ion solution is 0.01-0.3 mol/L.
所述方法还进一步包括对得到的高强度抗溶胀水凝胶型组织工程盂唇支架进行消毒的步骤。The method further includes the step of sterilizing the obtained high-strength anti-swelling hydrogel tissue-engineered labral scaffold.
上述方法制备得到的高强度抗溶胀水凝胶型组织工程盂唇支架也属于本发明的保护范围。The high-strength anti-swelling hydrogel tissue-engineered labral stent prepared by the above method also belongs to the protection scope of the present invention.
此外,上述提供的光敏树脂也属于本发明的保护范围。In addition, the photosensitive resin provided above also belongs to the protection scope of the present invention.
本发明还提供了上述光敏树脂的应用。The present invention also provides the application of the above-mentioned photosensitive resin.
本发明所提供的光敏树脂的应用,是其在光固化3D打印中的用途,尤其是在光固化立体成型(SLA)、数字光处理光固化3D打印(DLP)、连续液态界面(CLIP)打印中的用途。The application of the photosensitive resin provided by the present invention is its use in photocuring 3D printing, especially in photocuring three-dimensional molding (SLA), digital light processing photocuring 3D printing (DLP), continuous liquid interface (CLIP) printing use in.
以及,所述光敏树脂在制备水凝胶型组织工程盂唇支架中的应用。And, the application of the photosensitive resin in the preparation of a hydrogel tissue engineering labral scaffold.
与现有技术相比,本发明具有如下优点:Compared with the prior art, the present invention has the following advantages:
(1)本发明提供的水凝胶型盂唇支架具有优异的力学性能、抗溶胀特性及多孔结构,其力学性能与天然盂唇相近;(1) The hydrogel labral stent provided by the present invention has excellent mechanical properties, anti-swelling properties and porous structure, and its mechanical properties are similar to the natural labrum;
(2)本发明提供的水凝胶型盂唇支架具有良好的生物相容性、体内稳定性;(2) The hydrogel labral stent provided by the present invention has good biocompatibility and in vivo stability;
(3)本发明制备水凝胶型盂唇支架采用光固化3D打印的方式,打印精度高,可以精确控制其三维结构。(3) The preparation of the hydrogel labral support of the present invention adopts the method of photocuring 3D printing, the printing precision is high, and its three-dimensional structure can be precisely controlled.
附图说明Description of drawings
图1为通过数字光处理(DLP)3D打印制作的盂唇支架模型。Figure 1 shows a labral support model fabricated by digital light processing (DLP) 3D printing.
图2为实施例1-4中打印制作的盂唇支架以及天然盂唇的力学拉伸曲线。FIG. 2 is the mechanical stretching curve of the labral support and the natural labrum printed in Examples 1-4.
图3为将实施例1的盂唇支架植入猪髋臼关节,术后8周核磁共振T2像检查照片。Fig. 3 is a photograph of the labral stent implanted in the porcine acetabular joint of Example 1, and the MRI T2
图4为将实施例1的盂唇支架植入猪髋臼关节,术后8周解剖照片。Figure 4 is an anatomical photo of the labral stent of Example 1 implanted in the porcine acetabular joint 8 weeks after the operation.
图5为植入猪体内的支架周围关节滑膜组织病理HE染色照片。Fig. 5 is a HE-stained photo of the joint synovial tissue around the scaffold implanted in pigs.
图6为将猪的盂唇直接切除,术后8周髋臼和股骨头变化情况。Figure 6 shows the changes of the acetabulum and
具体实施方式Detailed ways
下面结合具体实施例对本发明作进一步阐述,但本发明并不限于以下实施例。所述方法如无特别说明均为常规方法。所述原材料如无特别说明均能从公开商业途径获得。The present invention will be further described below in conjunction with specific embodiments, but the present invention is not limited to the following embodiments. The methods are conventional methods unless otherwise specified. The raw materials can be obtained from open commercial sources unless otherwise specified.
实施例1Example 1
一种水性聚氨酯甲基丙烯酸酯乳液的制备,具体步骤如下:A kind of preparation of water-based polyurethane methacrylate emulsion, the concrete steps are as follows:
在装配有机械搅拌、氮气导入管、温度计和滴液漏斗的1 L 圆底烧瓶中,加入22.2g (0.1 mol) 异佛尔酮二异氰酸酯(IPDI),然后将20.0 g (0.01mol)聚己内酯二醇(分子量2000)、40.0 g(0.02)聚乙二醇(分子量2000)、6.03 g (0.045 mol)2,2 -二羟甲基丙酸和催化剂0.04 g月桂酸正丁基锡的混合物逐滴滴加到三口烧瓶中,此时保持瓶内反应体系温度90 °C。滴加完毕后,混合物继续反应,向体系中加入四氢呋喃降低粘度,通过傅里叶红外监测反应程度,当异氰酸酯基红外特征吸收峰不再减小时,再将0.05 g对苯二酚和 6.5g(0.05 mol)甲基丙烯酸羟乙酯的混合物逐滴加入体系中,期间保持体系温度60 °C。滴加完成后,继续反应,直至红外谱图中异氰酸酯基团的特征吸收峰完全消失,即得到聚氨酯丙烯酸酯。将体系温度降至室温,加入三乙胺中和分子链中的羧基,在高速搅拌(800 r/min)下逐滴加入去离子水284 g,经减压蒸馏除去有机溶剂,最终制得固含量为25%的水性聚氨酯甲基丙烯酸酯乳液-1(动态光散射测试平均粒径为45 nm)。In a 1 L round bottom flask equipped with mechanical stirring, nitrogen introduction tube, thermometer and dropping funnel, add 22.2 g (0.1 mol) isophorone diisocyanate (IPDI) followed by 20.0 g (0.01 mol) polyhexanol. A mixture of lactone diol (molecular weight 2000), 40.0 g (0.02) polyethylene glycol (molecular weight 2000), 6.03 g (0.045 mol) 2,2-dimethylolpropionic acid and catalyst 0.04 g n-butyltin laurate Add dropwise to the there-necked flask, keep the temperature of the reaction system in the flask at 90 °C. After the dropwise addition, the mixture continued to react, tetrahydrofuran was added to the system to reduce the viscosity, and the degree of reaction was monitored by Fourier infrared. 0.05 mol) of hydroxyethyl methacrylate was added dropwise to the system, while maintaining the system temperature at 60 °C. After the dropwise addition is completed, the reaction is continued until the characteristic absorption peak of the isocyanate group in the infrared spectrum disappears completely, that is, the urethane acrylate is obtained. The temperature of the system was lowered to room temperature, triethylamine was added to neutralize the carboxyl group in the molecular chain, 284 g of deionized water was added dropwise under high-speed stirring (800 r/min), and the organic solvent was removed by distillation under reduced pressure. Aqueous polyurethane methacrylate emulsion-1 with a content of 25% (average particle size measured by dynamic light scattering is 45 nm).
光固化3D打印水凝胶用光敏树脂的制备:Preparation of photosensitive resin for photocurable 3D printing hydrogel:
首先,按照配方比例称取原材料:光敏树脂的原料组分计按重量份数计含量如下:First, take by weighing the raw materials according to the formula ratio: the raw material components of the photosensitive resin are as follows in parts by weight:
水性聚氨酯甲基丙烯酸酯乳液-1 40份Waterborne Polyurethane Methacrylate Emulsion - 1 40 parts
丙烯酰胺 20份Acrylamide 20 servings
丙烯酸异冰片酯 19份19 parts of isobornyl acrylate
2-丙烯酰胺-2-甲基丙磺酸 20份2-Acrylamido-2-methylpropanesulfonic acid 20 parts
苯基双(2,4,6-三甲基苯甲酰基)氧化膦 1份Phenylbis(2,4,6-trimethylbenzoyl)phosphine oxide 1 part
然后,将各组分依次倒入搅拌器中,在避光的条件下通过超声细胞粉碎仪得到光敏树脂。Then, each component was poured into a stirrer in sequence, and the photosensitive resin was obtained by an ultrasonic cell crusher under the condition of avoiding light.
盂唇支架的打印:Printing of the labral support:
将制得的光敏树脂导入DLP 3D打印设备的树脂槽中进行模型打印,3D打印机的打印参数根据树脂固化速度和深度进行设定,得到表面光滑且精细度高的模型。打印完成后,将样件去除支撑,并放入乙醇中超声10 min,之后放入紫外箱后固化15 min,得到盂唇支架坯体。之后将盂唇支架坯体放入锆离子溶液中(浓度0.1 mol/L)浸泡三天,再放入去离子水中浸泡三天,最终得到3D打印高强度抗溶胀水凝胶型盂唇支架。The prepared photosensitive resin was introduced into the resin tank of the DLP 3D printing equipment for model printing. The printing parameters of the 3D printer were set according to the resin curing speed and depth, and a model with a smooth surface and high precision was obtained. After printing, the support was removed from the sample, placed in ethanol for sonication for 10 min, and then placed in a UV box for curing for 15 min to obtain a labral stent blank. After that, the labral stent blank was immersed in a zirconium ion solution (concentration 0.1 mol/L) for three days, and then in deionized water for three days. Finally, a 3D printed high-strength anti-swelling hydrogel labral stent was obtained.
实施例2Example 2
一种水性聚氨酯丙烯酸酯乳液的制备,具体步骤如下:A kind of preparation of water-based polyurethane acrylate emulsion, the concrete steps are as follows:
在装配有机械搅拌、氮气导入管、温度计和滴液漏斗的1 L 圆底烧瓶中,加入16.8g (0.1 mol)六亚甲基二异氰酸酯(HDI),然后将30.0 g(0.015 mol)聚己内酯二醇(分子量2000)、45.0 g (0.015 mol)聚四氢呋喃二醇(分子量为3000)、6.7 g (0.05 mol)2,2 -二羟甲基丙酸和0.02 辛酸亚锡的混合物逐滴滴加到三口烧瓶中,此时保持瓶内反应体系温度90 °C。滴加完毕后,混合物继续反应,向体系中加入四氢呋喃降低粘度,通过傅里叶红外监测反应程度,当异氰酸酯基红外特征吸收峰不再减小时,再将0.1 g对苯二酚和4.64 g(0.04 mol)丙烯酸羟乙酯的混合物逐滴加入体系中,期间保持体系温度55 °C。滴加完成后,继续反应,直至红外谱图中异氰酸酯基团的特征吸收峰完全消失,即得到聚氨酯丙烯酸酯。将体系温度降至室温,加入氨水中和分子链中的胺基,在高速搅拌(800 r/min)下逐滴加入去离子水309 g,经减压蒸馏除去有机溶剂,最终制得固含量为25 %的水性聚氨酯甲基丙烯酸酯乳液-2(动态光散射测试平均粒径为58 nm)。In a 1 L round bottom flask equipped with mechanical stirring, nitrogen introduction tube, thermometer and dropping funnel, add 16.8 g (0.1 mol) hexamethylene diisocyanate (HDI), then 30.0 g (0.015 mol) polyhexanol A mixture of lactone diol (molecular weight 2000), 45.0 g (0.015 mol) polytetrahydrofuran diol (molecular weight 3000), 6.7 g (0.05 mol) 2,2-dimethylolpropionic acid and 0.02 stannous octoate dropwise Dropwise into the there-necked flask, keep the temperature of the reaction system in the flask at 90 °C. After the dropwise addition, the mixture continued to react, tetrahydrofuran was added to the system to reduce the viscosity, and the degree of reaction was monitored by Fourier transform infrared spectroscopy. 0.04 mol) of hydroxyethyl acrylate was added dropwise to the system while maintaining the system temperature at 55 °C. After the dropwise addition is completed, the reaction is continued until the characteristic absorption peak of the isocyanate group in the infrared spectrum disappears completely, that is, the urethane acrylate is obtained. The temperature of the system was lowered to room temperature, ammonia water was added to neutralize the amine groups in the molecular chain, 309 g of deionized water was added dropwise under high-speed stirring (800 r/min), and the organic solvent was removed by distillation under reduced pressure, and finally the solid content was obtained. It is a 25 % aqueous polyurethane methacrylate emulsion-2 (average particle size measured by dynamic light scattering is 58 nm).
光固化3D打印水凝胶用光敏树脂的制备:Preparation of photosensitive resin for photocurable 3D printing hydrogel:
首先,按照配方比例称取原材料:光敏树脂的原料组分计按重量份数计含量如下:First, take by weighing the raw materials according to the formula ratio: the raw material components of the photosensitive resin are as follows in parts by weight:
水性聚氨酯丙烯酸酯乳液-2 45份Waterborne Polyurethane Acrylate Emulsion - 2 45 parts
丙烯酰胺 20份Acrylamide 20 servings
丙烯酸异冰片酯 22份22 parts of isobornyl acrylate
2-丙烯酰胺-2-甲基丙磺酸 11份2-Acrylamido-2-methylpropanesulfonic acid 11 parts
(2,4,6-三甲基苯甲酰基)二苯基氧化膦 2份(2,4,6-trimethylbenzoyl)
然后,将各组分依次倒入搅拌器中,在避光的条件下通过超声细胞粉碎仪得到光敏树脂。Then, each component was poured into a stirrer in sequence, and the photosensitive resin was obtained by an ultrasonic cell crusher under the condition of avoiding light.
盂唇支架的打印:Printing of the labral support:
将制得的光敏树脂导入DLP 3D打印设备的树脂槽中进行模型打印,3D打印机的打印参数根据树脂固化速度和深度进行设定,得到表面光滑且精细度高的模型。打印完成后,将样件去除支撑,并放入乙醇中超声10 min,之后放入紫外箱后固化15 min,得到盂唇支架坯体。之后将盂唇支架坯体放入锆离子溶液中(浓度0.1 mol/L)浸泡三天,再放入去离子水中浸泡三天,最终得到3D打印高强度抗溶胀水凝胶型盂唇支架。The prepared photosensitive resin was introduced into the resin tank of the DLP 3D printing equipment for model printing. The printing parameters of the 3D printer were set according to the resin curing speed and depth, and a model with a smooth surface and high precision was obtained. After printing, the support was removed from the sample, placed in ethanol for sonication for 10 min, and then placed in a UV box for curing for 15 min to obtain a labral stent blank. After that, the labral stent blank was immersed in a zirconium ion solution (concentration 0.1 mol/L) for three days, and then in deionized water for three days. Finally, a 3D printed high-strength anti-swelling hydrogel labral stent was obtained.
实施例3Example 3
一种水性聚氨酯丙烯酸酯乳液的制备,具体步骤如下:A kind of preparation of water-based polyurethane acrylate emulsion, the concrete steps are as follows:
在装配有机械搅拌、氮气导入管、温度计和滴液漏斗的1 L 圆底烧瓶中,加入16.8g (0.1 mol)六亚甲基二异氰酸酯(HDI),然后将100.0 g(0.05 mol)聚乙二醇(分子量2000)、60.0 g (0.03 mol)聚丙二醇(分子量为2000)、0.02 g 月桂酸正丁基锡的混合物逐滴滴加到三口烧瓶中,此时保持瓶内反应体系温度90 °C。滴加完毕后,混合物继续反应,通过傅里叶红外监测反应程度,当异氰酸酯基红外特征吸收峰不再减小时,再将0.1 g对苯二酚和4.64 g(0.04 mol)丙烯酸羟乙酯的混合物逐滴加入体系中,期间保持体系温度55 °C。滴加完成后,继续反应,直至红外谱图中异氰酸酯基团的特征吸收峰完全消失,即得到聚氨酯丙烯酸酯。将体系温度降至室温,在高速搅拌(800 r/min)下逐滴加入去离子水544 g,经减压蒸馏除去有机溶剂,最终制得固含量为25 %的水性聚氨酯丙烯酸酯乳液-3(动态光散射测试平均粒径为46 nm)。In a 1 L round-bottomed flask equipped with mechanical stirring, nitrogen introduction tube, thermometer and dropping funnel, add 16.8 g (0.1 mol) hexamethylene diisocyanate (HDI) followed by 100.0 g (0.05 mol) polyethylene A mixture of diol (molecular weight 2000), 60.0 g (0.03 mol) polypropylene glycol (molecular weight 2000), and 0.02 g n-butyltin laurate was added dropwise to the three-necked flask, while the temperature of the reaction system in the flask was maintained at 90 °C. After the dropwise addition, the mixture continued to react, and the degree of reaction was monitored by Fourier infrared. When the infrared characteristic absorption peak of the isocyanate group was no longer reduced, 0.1 g of hydroquinone and 4.64 g (0.04 mol) of hydroxyethyl acrylate were added together. The mixture was added dropwise to the system while maintaining the system temperature at 55°C. After the dropwise addition is completed, the reaction is continued until the characteristic absorption peak of the isocyanate group in the infrared spectrum disappears completely, that is, the urethane acrylate is obtained. The temperature of the system was lowered to room temperature, 544 g of deionized water was added dropwise under high-speed stirring (800 r/min), and the organic solvent was removed by distillation under reduced pressure, and finally a water-based polyurethane acrylate emulsion-3 with a solid content of 25 % was obtained. (Dynamic light scattering test has an average particle size of 46 nm).
光固化3D打印水凝胶用光敏树脂的制备:Preparation of photosensitive resin for photocurable 3D printing hydrogel:
首先,按照配方比例称取原材料:光敏树脂的原料组分计按重量份数计含量如下:First, take by weighing the raw materials according to the formula ratio: the raw material components of the photosensitive resin are as follows in parts by weight:
水性聚氨酯丙烯酸酯乳液-3 45份Waterborne Polyurethane Acrylate Emulsion - 3 45 parts
N-异丙基丙烯酰胺 20份N-isopropylacrylamide 20 parts
丙烯酸异冰片酯 10份Isobornyl Acrylate 10 parts
3-磺丙基丙烯酸酯钾盐 24份3-sulfopropyl acrylate potassium salt 24 parts
苯基双(2,4,6-三甲基苯甲酰基)氧化膦 1份Phenylbis(2,4,6-trimethylbenzoyl)phosphine oxide 1 part
然后,将各组分依次倒入搅拌器中,在避光的条件下通过超声细胞粉碎仪得到光敏树脂。Then, each component was poured into a stirrer in sequence, and the photosensitive resin was obtained by an ultrasonic cell crusher under the condition of avoiding light.
盂唇支架的打印:Printing of the labral support:
将制得的光敏树脂导入DLP 3D打印设备的树脂槽中进行模型打印,3D打印机的打印参数根据树脂固化速度和深度进行设定,得到表面光滑且精细度高的模型。打印完成后,将样件去除支撑,并放入乙醇中超声10 min,之后放入紫外箱后固化15 min,得到盂唇支架坯体。之后将盂唇支架坯体放入锆离子溶液中(浓度0.1 mol/L)浸泡三天,再放入去离子水中浸泡三天,最终得到3D打印高强度抗溶胀水凝胶型盂唇支架。The prepared photosensitive resin was introduced into the resin tank of the DLP 3D printing equipment for model printing. The printing parameters of the 3D printer were set according to the resin curing speed and depth, and a model with a smooth surface and high precision was obtained. After printing, the support was removed from the sample, placed in ethanol for 10 min of ultrasound, and then placed in a UV oven for 15 min of curing to obtain a labral stent blank. After that, the labral stent blank was soaked in a zirconium ion solution (concentration 0.1 mol/L) for three days, and then in deionized water for three days, and finally a 3D printed high-strength anti-swelling hydrogel labral stent was obtained.
实施例4Example 4
一种水性聚氨酯丙烯酸酯乳液的制备,具体步骤如下:A kind of preparation of water-based polyurethane acrylate emulsion, the concrete steps are as follows:
在装配有机械搅拌、氮气导入管、温度计和滴液漏斗的1 L 圆底烧瓶中,加入22.2g (0.1 mol)异佛尔酮二异氰酸酯(IPDI),然后将40.0 g(0.04 mol)聚乙二醇(分子量1000)、75.0 g (0.015 mol) 聚乙二醇(分子量5000)、60.0 g (0.03 mol)聚己内酯二醇(分子量为2000)、0.02 g 月桂酸正丁基锡的混合物逐滴滴加到三口烧瓶中,此时保持瓶内反应体系温度90 °C。滴加完毕后,混合物继续反应,通过傅里叶红外监测反应程度,当异氰酸酯基红外特征吸收峰不再减小时,再将0.1 g对苯二酚和3.90 g(0.03 mol)甲基丙烯酸羟乙酯的混合物逐滴加入体系中,期间保持体系温度55 °C。滴加完成后,继续反应,直至红外谱图中异氰酸酯基团的特征吸收峰完全消失,即得到聚氨酯丙烯酸酯。将体系温度降至室温,在高速搅拌(800 r/min)下逐滴加入去离子水603 g,经减压蒸馏除去有机溶剂,最终制得固含量为25 %的水性聚氨酯丙烯酸酯乳液-4(动态光散射测试平均粒径为52 nm)。In a 1 L round bottom flask equipped with mechanical stirring, nitrogen introduction tube, thermometer and dropping funnel, add 22.2 g (0.1 mol) isophorone diisocyanate (IPDI) followed by 40.0 g (0.04 mol) polyethylene A mixture of diol (molecular weight 1000), 75.0 g (0.015 mol) polyethylene glycol (molecular weight 5000), 60.0 g (0.03 mol) polycaprolactone diol (molecular weight 2000), 0.02 g n-butyltin laurate dropwise Dropwise into the there-necked flask, keep the temperature of the reaction system in the flask at 90 °C. After the dropwise addition, the mixture continued to react, and the degree of reaction was monitored by Fourier infrared. When the characteristic absorption peak of the isocyanate group was no longer reduced, 0.1 g of hydroquinone and 3.90 g (0.03 mol) of hydroxyethyl methacrylate were added to the mixture. The ester mixture was added dropwise to the system while maintaining the system temperature at 55°C. After the dropwise addition is completed, the reaction is continued until the characteristic absorption peak of the isocyanate group in the infrared spectrum disappears completely, that is, the urethane acrylate is obtained. The temperature of the system was lowered to room temperature, 603 g of deionized water was added dropwise under high-speed stirring (800 r/min), and the organic solvent was removed by distillation under reduced pressure, and finally an aqueous polyurethane acrylate emulsion-4 with a solid content of 25 % was obtained. (Dynamic light scattering test has an average particle size of 52 nm).
光固化3D打印水凝胶用光敏树脂的制备:Preparation of photosensitive resin for photocurable 3D printing hydrogel:
首先,按照配方比例称取原材料:光敏树脂的原料组分计按重量份数计含量如下:First, take by weighing the raw materials according to the formula ratio: the raw material components of the photosensitive resin are as follows in parts by weight:
水性聚氨酯丙烯酸酯乳液-4 34份Waterborne Polyurethane Acrylate Emulsion - 4 34 parts
N-异丙基丙烯酰胺 30份N-isopropylacrylamide 30 parts
丙烯腈 10份Acrylonitrile 10 parts
乙烯基磺酸钠 25份25 parts of sodium vinyl sulfonate
(2,4,6-三甲基苯甲酰基)二苯基氧化膦 1份(2,4,6-trimethylbenzoyl)diphenylphosphine oxide 1 part
然后,将各组分依次倒入搅拌器中,在避光的条件下通过超声细胞粉碎仪得到光敏树脂。Then, each component was poured into a stirrer in sequence, and the photosensitive resin was obtained by an ultrasonic cell crusher under the condition of avoiding light.
盂唇支架的打印:Printing of the labral support:
将制得的光敏树脂导入DLP 3D打印设备的树脂槽中进行模型打印,3D打印机的打印参数根据树脂固化速度和深度进行设定,得到表面光滑且精细度高的模型。打印完成后,将样件去除支撑,并放入乙醇中超声10 min,之后放入紫外箱后固化15 min,得到盂唇支架坯体。之后将盂唇支架坯体放入锆离子溶液中(浓度0.1 mol/L)浸泡三天,再放入去离子水中浸泡三天,最终得到3D打印高强度抗溶胀水凝胶型盂唇支架。The prepared photosensitive resin was introduced into the resin tank of the DLP 3D printing equipment for model printing. The printing parameters of the 3D printer were set according to the resin curing speed and depth, and a model with a smooth surface and high precision was obtained. After printing, the support was removed from the sample, placed in ethanol for sonication for 10 min, and then placed in a UV box for curing for 15 min to obtain a labral stent blank. After that, the labral stent blank was immersed in a zirconium ion solution (concentration 0.1 mol/L) for three days, and then in deionized water for three days. Finally, a 3D printed high-strength anti-swelling hydrogel labral stent was obtained.
对比例1Comparative Example 1
光固化3D打印水凝胶用光敏树脂的制备:Preparation of photosensitive resin for photocurable 3D printing hydrogel:
首先,按照配方比例称取原材料:光敏树脂的原料组分计按重量份数计含量如下:First, take by weighing the raw materials according to the formula ratio: the raw material components of the photosensitive resin are as follows in parts by weight:
水性聚氨酯丙烯酸酯乳液-1(同实施例1) 45份45 parts of water-based polyurethane acrylate emulsion-1 (same as Example 1)
丙烯酰胺 44份Acrylamide 44 servings
丙烯酸异冰片酯 10份Isobornyl Acrylate 10 parts
(2,4,6-三甲基苯甲酰基)二苯基氧化膦 1份(2,4,6-trimethylbenzoyl)diphenylphosphine oxide 1 part
然后,将各组分依次倒入搅拌器中,在避光的条件下通过超声细胞粉碎仪得到光敏树脂。Then, each component was poured into a stirrer in sequence, and the photosensitive resin was obtained by an ultrasonic cell crusher under the condition of avoiding light.
水凝胶样品的打印:Printing of hydrogel samples:
将制得的光敏树脂导入DLP 3D打印设备的树脂槽中进行模型打印,3D打印机的打印参数根据树脂固化速度和深度进行设定,得到表面光滑且精细度高的模型。打印完成后,将样件去除支撑,并放入乙醇中超声10 min,之后放入紫外箱后固化15 min,得到水凝胶支架。The prepared photosensitive resin was introduced into the resin tank of the DLP 3D printing equipment for model printing. The printing parameters of the 3D printer were set according to the resin curing speed and depth, and a model with a smooth surface and high precision was obtained. After the printing was completed, the support was removed from the sample, placed in ethanol for sonication for 10 min, and then placed in a UV box for curing for 15 min to obtain a hydrogel scaffold.
对比例2Comparative Example 2
将对比例1所得水凝胶样品,放入去离子水中浸泡三天,得到溶胀平衡后的水凝胶样品。The hydrogel sample obtained in Comparative Example 1 was soaked in deionized water for three days to obtain a hydrogel sample after swelling equilibrium.
对上述实施例及对比例制备的盂唇支架的力学性能评价,按照GB/T2567-2008测试标准对打印的盂唇支架和水凝胶样品进行力学性能评价包括拉伸强度、断裂伸长率。结果见表1。For the evaluation of the mechanical properties of the labral stents prepared in the above examples and comparative examples, the mechanical properties of the printed labral stents and hydrogel samples were evaluated according to the GB/T2567-2008 test standard, including tensile strength and elongation at break. The results are shown in Table 1.
表1Table 1
表1 为实施例和对比例制备的水凝胶样品的力学性能和含水率结果。实施例结果表明经过磺酸基团和锆离子形成离子配位键后,水凝胶具有优异的力学性能和抗溶胀性能。对比例中水凝胶中不含磺酸基团,在去离子水中浸泡后,水凝胶溶胀1.6倍,力学性能下降明显。Table 1 shows the mechanical properties and water content results of the hydrogel samples prepared in Examples and Comparative Examples. The results of the examples show that the hydrogel has excellent mechanical properties and anti-swelling properties after the formation of ionic coordination bonds between sulfonic acid groups and zirconium ions. The hydrogel in the comparative example does not contain sulfonic acid groups. After soaking in deionized water, the hydrogel swells by 1.6 times, and the mechanical properties decrease significantly.
图1为通过数字光处理(DLP)3D打印制作的盂唇支架模型。Figure 1 shows a labral support model fabricated by digital light processing (DLP) 3D printing.
图2为实施例1-4中打印制作的盂唇支架以及天然盂唇的力学拉伸曲线,其拉伸强度与天然盂唇相似。FIG. 2 shows the mechanical tensile curves of the labral support and the natural labrum printed in Examples 1-4, and the tensile strength is similar to that of the natural labrum.
盂唇支架的体内效果验证:In vivo effect verification of labral stent:
将6个月大雄性猪进行麻醉和皮肤消毒后,在髋关节部位做s形切口,在切开髋关节囊后,暴露盂唇,用手术刀制作1.5厘米长的唇缺陷。之后,将水凝胶盂唇支架植入缺陷,并进行固定缝合。After 6-month-old male pigs were anesthetized and skin sterilized, an S-shaped incision was made at the hip joint site. After the hip joint capsule was incised, the labrum was exposed, and a 1.5 cm-long lip defect was made with a scalpel. Afterwards, the hydrogel labral stent was implanted into the defect and fixed with sutures.
图3显示为将实施例1的盂唇支架植入猪髋臼关节,术后8周核磁共振T2像检查照片,图中显示(箭头所示)盂唇支架在关节间隙中结构完整,关节软骨未见明显破坏,支架周围有自体组织长入。Figure 3 shows the implantation of the labral scaffold of Example 1 into the pig acetabular joint, and the MRI T2
图4为将实施例1的盂唇支架植入猪髋臼关节,术后8周解剖照片,术后8周内髋臼和股骨头软骨未见明显骨性关节炎,关节软骨状态良好,说明本发明水凝胶支架起到了良好保护关节软骨的作用。Fig. 4 is implantation of the labral support of Example 1 into the pig acetabular joint,
图5为支架周围关节滑膜组织病理HE染色照片,结果显示滑膜状态良好,无明显炎症反应。Figure 5 is a HE staining photo of the joint synovium tissue around the stent. The results show that the synovium is in good condition and there is no obvious inflammatory reaction.
图6为将猪的盂唇直接切除,术后8周髋臼和股骨头未见自体组织生长。Figure 6 shows the direct excision of the labrum of the pig, and no autologous tissue growth was found in the acetabulum and
本发明制备的水凝胶型组织工程盂唇支架具有良好的生物相容性和体内稳定性,其力学性能与天然盂唇相近,而且打印精度高,可以定制特定三维结构和多孔结构的盂唇支架。The hydrogel tissue engineering labrum scaffold prepared by the invention has good biocompatibility and in vivo stability, its mechanical properties are similar to the natural labrum, and the printing precision is high, and the labrum with specific three-dimensional structure and porous structure can be customized bracket.
尽管已经示出和描述了本发明的实施例,对于本领域的普通技术人员而言,可以理解在不脱离本发明的原理和精神的情况下可以对这些实施例进行多种变化、修改、替换和变形,本发明的范围由所附权利要求极其等同限定。Although embodiments of the present invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, and substitutions can be made in these embodiments without departing from the principle and spirit of the invention and variations, the scope of the present invention is defined by the appended claims with full equivalents.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210786271.9A CN114835862B (en) | 2022-07-06 | 2022-07-06 | Hydrogel type tissue engineering labrum bracket, photocuring 3D printing preparation method thereof and photosensitive resin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210786271.9A CN114835862B (en) | 2022-07-06 | 2022-07-06 | Hydrogel type tissue engineering labrum bracket, photocuring 3D printing preparation method thereof and photosensitive resin |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114835862A true CN114835862A (en) | 2022-08-02 |
CN114835862B CN114835862B (en) | 2022-09-13 |
Family
ID=82575281
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210786271.9A Active CN114835862B (en) | 2022-07-06 | 2022-07-06 | Hydrogel type tissue engineering labrum bracket, photocuring 3D printing preparation method thereof and photosensitive resin |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114835862B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116198113A (en) * | 2023-03-06 | 2023-06-02 | 南方医科大学 | Preparation method of photocuring 3D printing PU prosthesis |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105038665A (en) * | 2015-08-27 | 2015-11-11 | 常州大学 | Ultraviolet curing medical conductive pressure-sensitive adhesive and preparation method thereof |
CN105592865A (en) * | 2013-08-01 | 2016-05-18 | 因特里斯伍有限公司 | Hydrogel fibers and preparation thereof |
CN107828031A (en) * | 2017-11-03 | 2018-03-23 | 温州大学 | A kind of aqueous polyurethane acrylate grafting keratin hydrogel and preparation method thereof |
CN113045708A (en) * | 2021-03-17 | 2021-06-29 | 中国科学院化学研究所 | Photosensitive resin for photocuring 3D printing hydrogel and preparation method and application thereof |
CN113801272A (en) * | 2021-09-14 | 2021-12-17 | 中国科学院化学研究所 | A self-healing and 3D printable ionic gel and its preparation and application |
US20220088851A1 (en) * | 2019-03-25 | 2022-03-24 | Virginia Tech Intellectual Properties, Inc. | Synthesis and 3d printing of photocurable colloids |
CN114349913A (en) * | 2022-01-26 | 2022-04-15 | 中国科学院化学研究所 | A kind of photosensitive resin for preparing single-network high-strength and high-toughness hydrogel and its application in photocuring 3D printing |
-
2022
- 2022-07-06 CN CN202210786271.9A patent/CN114835862B/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105592865A (en) * | 2013-08-01 | 2016-05-18 | 因特里斯伍有限公司 | Hydrogel fibers and preparation thereof |
CN105038665A (en) * | 2015-08-27 | 2015-11-11 | 常州大学 | Ultraviolet curing medical conductive pressure-sensitive adhesive and preparation method thereof |
CN107828031A (en) * | 2017-11-03 | 2018-03-23 | 温州大学 | A kind of aqueous polyurethane acrylate grafting keratin hydrogel and preparation method thereof |
US20220088851A1 (en) * | 2019-03-25 | 2022-03-24 | Virginia Tech Intellectual Properties, Inc. | Synthesis and 3d printing of photocurable colloids |
CN113045708A (en) * | 2021-03-17 | 2021-06-29 | 中国科学院化学研究所 | Photosensitive resin for photocuring 3D printing hydrogel and preparation method and application thereof |
CN113801272A (en) * | 2021-09-14 | 2021-12-17 | 中国科学院化学研究所 | A self-healing and 3D printable ionic gel and its preparation and application |
CN114349913A (en) * | 2022-01-26 | 2022-04-15 | 中国科学院化学研究所 | A kind of photosensitive resin for preparing single-network high-strength and high-toughness hydrogel and its application in photocuring 3D printing |
Non-Patent Citations (1)
Title |
---|
张文君等: "新型水性紫外光固化聚氨酯丙烯酸酯的制备及性能", 《涂料工业》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116198113A (en) * | 2023-03-06 | 2023-06-02 | 南方医科大学 | Preparation method of photocuring 3D printing PU prosthesis |
CN116198113B (en) * | 2023-03-06 | 2024-10-22 | 南方医科大学 | Preparation method of photocuring 3D printing PU prosthesis |
Also Published As
Publication number | Publication date |
---|---|
CN114835862B (en) | 2022-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
He et al. | 3D printed biomimetic epithelium/stroma bilayer hydrogel implant for corneal regeneration | |
Pereira et al. | Photopolymerizable and injectable polyurethanes for biomedical applications: Synthesis and biocompatibility | |
Voldřrich et al. | Long‐term experience with poly (glycol monomethacrylate) gel in plastic operations of the nose | |
US6129761A (en) | Injectable hydrogel compositions | |
Wang et al. | Photo-crosslinked poly (ε-caprolactone fumarate) networks for guided peripheral nerve regeneration: Material properties and preliminary biological evaluations | |
US8574311B2 (en) | Versatile biodegradable elastic polymers featured with dual crosslinking mechanism for biomedical applications | |
CN108653809B (en) | A composite hydrogel based on black phosphorus and gelatin and its application in bone tissue engineering | |
JP3962715B2 (en) | Use of autologous dermal fibroblasts to repair skin and soft tissue defects | |
DE69737909T2 (en) | POLYMERIZABLE BIODEGRADABLE POLYMERS WITH CARBONATE OR DIOXANONE BINDINGS | |
KR101019374B1 (en) | Medical Cationic Alkyd Polyester | |
DE60313533T2 (en) | Injectable compositions for medical applications | |
Laube et al. | In situ foamable, degradable polyurethane as biomaterial for soft tissue repair | |
TW200403268A (en) | Biodegradable polyurethane/urea compositions | |
US8282912B2 (en) | Compositions for tissue augmentation | |
Ding et al. | Meniscal transplantation and regeneration using functionalized polyurethane bionic scaffold and digital light processing 3D printing | |
CN117567698B (en) | Photo-curing biocompatible material and drainage tube | |
CN114835862B (en) | Hydrogel type tissue engineering labrum bracket, photocuring 3D printing preparation method thereof and photosensitive resin | |
CN112220968B (en) | A light-curing 3D printing preparation method of a long-term alternative tissue engineering meniscus scaffold | |
JP4002299B2 (en) | Improved hydrogel for tissue treatment | |
BG107397A (en) | Polyacrylamide hydrogel and its use as an endoprosthesis | |
US20220218465A1 (en) | Modified extracellular matrix-based hydrogel, manufacturing method of the same and use of the same | |
CN112220969B (en) | Photocuring 3D printing preparation method of degradable meniscus support | |
CN115154663B (en) | Hydrogel-type tissue engineering scaffold with biphasic drug sustained release function and its photocuring 3D printing preparation method, photosensitive resin | |
KR100776297B1 (en) | Injection type photocrosslinking hydrogel, biodegradable graft tissue, injection drug delivery preparation and preparation method thereof | |
CN112007213B (en) | Osteochondral repair bionic material and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |